Cargando…

Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report

Mesenchymal stem cell (MSC) transplant may offer an alternative to liver transplantation in patients with end‐stage liver disease. However, its efficacy remains uncertain. MSC was performed on a 50‐year‐old male with decompensated (Child‐Turcotte‐Pugh grade C) alcoholic liver cirrhosis due to an abs...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajaram, Ruveena, Subramani, Baskar, Abdullah, Basri J J, Mahadeva, Sanjiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206997/
https://www.ncbi.nlm.nih.gov/pubmed/30483553
http://dx.doi.org/10.1002/jgh3.12027
_version_ 1783366462659887104
author Rajaram, Ruveena
Subramani, Baskar
Abdullah, Basri J J
Mahadeva, Sanjiv
author_facet Rajaram, Ruveena
Subramani, Baskar
Abdullah, Basri J J
Mahadeva, Sanjiv
author_sort Rajaram, Ruveena
collection PubMed
description Mesenchymal stem cell (MSC) transplant may offer an alternative to liver transplantation in patients with end‐stage liver disease. However, its efficacy remains uncertain. MSC was performed on a 50‐year‐old male with decompensated (Child‐Turcotte‐Pugh grade C) alcoholic liver cirrhosis due to an absence of donors for adult‐deceased and living‐related liver transplantation. Autologous bone marrow‐derived MSCs were harvested from the patient and cultured using standard protocols. The MSCs were subsequently re‐administrated into the liver via hepatic intra‐arterial infusion on two separate occasions. After infusion, there was an improvement in biochemical parameters (serum total bilirubin, serum albumin), and a reduction of diuretic use for ascites for up to 8 weeks. However, all biochemical and clinical parameters deteriorated on long‐term follow‐up without any further infusions. The patient eventually succumbed to his disease. MSC transplantation may have a clinical benefit on adult patients with end‐stage liver cirrhosis, but this appears to be transitory.
format Online
Article
Text
id pubmed-6206997
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-62069972018-11-27 Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report Rajaram, Ruveena Subramani, Baskar Abdullah, Basri J J Mahadeva, Sanjiv JGH Open Case Report Mesenchymal stem cell (MSC) transplant may offer an alternative to liver transplantation in patients with end‐stage liver disease. However, its efficacy remains uncertain. MSC was performed on a 50‐year‐old male with decompensated (Child‐Turcotte‐Pugh grade C) alcoholic liver cirrhosis due to an absence of donors for adult‐deceased and living‐related liver transplantation. Autologous bone marrow‐derived MSCs were harvested from the patient and cultured using standard protocols. The MSCs were subsequently re‐administrated into the liver via hepatic intra‐arterial infusion on two separate occasions. After infusion, there was an improvement in biochemical parameters (serum total bilirubin, serum albumin), and a reduction of diuretic use for ascites for up to 8 weeks. However, all biochemical and clinical parameters deteriorated on long‐term follow‐up without any further infusions. The patient eventually succumbed to his disease. MSC transplantation may have a clinical benefit on adult patients with end‐stage liver cirrhosis, but this appears to be transitory. Wiley Publishing Asia Pty Ltd 2017-12-07 /pmc/articles/PMC6206997/ /pubmed/30483553 http://dx.doi.org/10.1002/jgh3.12027 Text en © 2017 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Rajaram, Ruveena
Subramani, Baskar
Abdullah, Basri J J
Mahadeva, Sanjiv
Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report
title Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report
title_full Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report
title_fullStr Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report
title_full_unstemmed Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report
title_short Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report
title_sort mesenchymal stem cell therapy for advanced liver cirrhosis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206997/
https://www.ncbi.nlm.nih.gov/pubmed/30483553
http://dx.doi.org/10.1002/jgh3.12027
work_keys_str_mv AT rajaramruveena mesenchymalstemcelltherapyforadvancedlivercirrhosisacasereport
AT subramanibaskar mesenchymalstemcelltherapyforadvancedlivercirrhosisacasereport
AT abdullahbasrijj mesenchymalstemcelltherapyforadvancedlivercirrhosisacasereport
AT mahadevasanjiv mesenchymalstemcelltherapyforadvancedlivercirrhosisacasereport